RenovoRx, Inc. — Form 8-K
Filed July 2, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 78/100
What the filing says
RenovoRx received notice on July 1, 2026, that it has been granted an additional 180-calendar-day compliance period (until December 28, 2026) to regain compliance with Nasdaq's $1.00 minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)). The company initially received a deficiency notice on December 31, 2025, with a 180-day cure period ending June 30, 2026. If the stock closes at $1.00+ per share for 10 consecutive business days by December 28, 2026, Nasdaq will confirm compliance; otherwise, delisting proceedings commence with potential appeal rights.
Why this rating
Second-chance reprieve from delisting is moderately significant for a $26.6M-cap company—failure in 6 months could trigger delisting and loss of Nasdaq listing, materially damaging equity value and market access.
Extracted items
See more from July 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.